Assessment of antihistamines in the treatment of skin allergies

Current Opinion in Allergy and Clinical Immunology

Volumn 11, Issue 5, 2011, Pages 428-437

  Murota, Hiroyuki ^a   Katayama, Ichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

antihistamine; pharmacological property; quality of life; sedation; skin allergy

Indexed keywords

AMPHIREGULIN; ANTIHISTAMINIC AGENT; AUTOANTIBODY; BETOTASTINE; CAREBASTINE; CETIRIZINE; CHEMOREPELLENT; CHLORPHENIRAMINE; DESLORATADINE; DEXBROMPHENIRAMINE; DIPHENHYDRAMINE; EMEDASTINE; EPINASTINE; FEXOFENADINE; HISTAMINE; HISTAMINE H1 RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; KETOTIFEN; LEVOCETIRIZINE; LORATADINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MIZOLASTINE; NERVE GROWTH FACTOR; OLOPATADINE; RUPATADINE; SEDATIVE AGENT; SEMAPHORIN 3A; SUBSTANCE P;

ACCIDENT; ACUTE DISEASE; ADJUVANT THERAPY; ANTIGEN EXPRESSION; ATOPIC DERMATITIS; ATTENTION; BEDTIME DOSAGE; CELL ADHESION; CELL SURVIVAL; CHRONIC URTICARIA; COGNITIVE DEFECT; COLD URTICARIA; CYTOKINE PRODUCTION; DAILY LIFE ACTIVITY; DIET; DISEASE SEVERITY; DRIVING ABILITY; DRUG CLASSIFICATION; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG PENETRATION; DRUG SAFETY; ENDOTHELIUM CELL; EOSINOPHIL; EXPERIMENTAL MODEL; FIBROBLAST; HOMEOSTASIS; HORMONE RELEASE; HUMAN; IDIOPATHIC DISEASE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; INFECTION; INFECTION SENSITIVITY; INFLAMMATION; INNATE IMMUNITY; KERATINOCYTE; LANGERHANS CELL; MAST CELL DEGRANULATION; MEMORY; MORBIDITY; MULTICENTER STUDY (TOPIC); NERVE CELL MEMBRANE STEADY POTENTIAL; NERVE ELONGATION; NERVE ENDING; NERVE EXCITABILITY; NERVE FIBER; NERVE FIBER C; NONHUMAN; OBESITY; PATIENT CARE; PATIENT COMPLIANCE; PERITONITIS; PLEIOTROPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; PSYCHOMOTOR ACTIVITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; SKIN ALLERGY; SKIN CELL; SLEEP DISORDER; STIMULUS; TARGET CELL; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; UPREGULATION; URTICARIA;

ABSENTEEISM; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; HYPERSENSITIVITY; IMMUNOMODULATION; INDIVIDUALIZED MEDICINE; QUALITY OF LIFE; RECEPTORS, HISTAMINE H1; RISK ASSESSMENT; SKIN; URTICARIA;

EID: 80052447025     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32834a96e9     Document Type: Review

References (78)

1. Akdis CA, Simons FE. Histamine receptors are hot in immunopharmacology. Eur J Pharmacol 2006; 533:69-76 (Pubitemid 43340005)
2. Murota H, Katayama I. Emedastine difumarate: a review of its potential ameliorating effect for tissue remodeling in allergic diseases. Expert Opin Pharmacother 2009; 10:1859-1867
3. Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64:1427-1443
4. Powell RJ, Du Toit GL, Siddique N, et al. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy 2007; 37:631-650 (Pubitemid 46643051)
5. Tedeschi A, Girolomoni G, Asero R. AAITO Position paper. Chronic urticaria: diagnostic workup and treatment. Eur Ann Allergy Clin Immunol 2007; 39:225-231
6. Joint Task Force on Practice Parameters. The diagnosis and management of urticaria: a practice parameter part I: acute urticaria/angioedema part II: chronic urticaria/angioedema. Joint Task Force on Practice Parameters. Ann Allergy Asthma Immunol 2000; 85:521-544
7. Hide M, Furue M, Ikezawa Z, et al. Guidelines for the diagnosis and treatment of urticaria and angioedema [in Japanese]. Jpn J Dermatol 2005; 115:703-715
8. Schulz S, Metz M, Siepmann D, et al. Antipruritic efficacy of a high-dosage antihistamine therapy: results of a retrospectively analysed case series. Hautarzt 2009; 60:564-568
9. Williams HC. Clinical practice. Atopic dermatitis. N Engl J Med 2005; 352:2314-2324
10. Klein PA, Clark RA. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol 1999; 135:1522-1525
11. Hanifin JM, Cooper KD, Ho VC, et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/ American Academy of Dermatology Association 'Administrative Regulations for Evidence-Based Clinical Practice Guidelines?. J Am Acad Dermatol 2004; 50:391-404
12. Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/ PRACTALL Consensus Report. Allergy 2006; 61:969-987 (Pubitemid 44024897)
13. Lewis-Jones S, Mugglestone MA. Management of atopic eczema in children aged up to12 years: summary of NICEguidance.BMJ2007; 335:1263-1264
14. Leung DY, Nicklas RA, Li JT, et al. Disease management of atopic dermatitis: an updated practice parameter. Joint Task Force on Practice Parameters. Ann Allergy Asthma Immunol 2004; 93:S1-S21 (Pubitemid 39274348)
15. Saeki H, Furue M, Furukawa F, et al. Guidelines for management of atopic dermatitis. J Dermatol 2009; 36:563-577
16. Kawashima M, Tango T, Noguchi T, et al. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1- week randomized, multicentre, double-blind, placebo-controlled, parallelgroup study. Br J Dermatol 2003; 148:1212-1221 (Pubitemid 36819222)
17. Kawashima M, Harada S. Effect of standard medication on quality of life of patients with atopic dermatitis. J Dermatol 2007; 34:9-16 (Pubitemid 46005951)
18. Kawashima M, Harada S. A study of the effect on itch and quality of life of atopic dermatitis patients treated by standard therapy with antiallergic drug [in Japanese]. Jpn J Clin Dermatol 2006; 60:661-667
19. Kobayashi M, Kabashima K, Nakamura M, et al. Downmodulatory effects of the antihistaminic drug bepotastine on cytokine/chemokine production and CD54 expression in human keratinocytes. Skin Pharmacol Physiol 2009; 22:45-48
20. Xia Q, Yang S, Zhang SQ, et al. The effect of mizolastine on expression of vascular endothelial cell growth factor, tumour necrosis factor-alpha and keratinocyte-derived chemokine in murine mast cells, compared with dexamethasone and loratadine. Clin Exp Dermatol 2005; 30:165-170 (Pubitemid 40380096)
21. Giustizieri ML, Albanesi C, Fluhr J, et al. H1 histamine receptor mediates inflammatory responses in human keratinocytes. J Allergy Clin Immunol 2004; 114:1176-1182 (Pubitemid 39469162)
22. Kobayashi M, Kabashima K, Tokura Y. Inhibitory effects of epinastine on chemokine production and MHC class II/CD54 expression in keratinocytes. J Dermatol Sci 2007; 45:144-146 (Pubitemid 46108482)
23. Kobayashi M, Tokura Y. Preferential downmodulation of certain chemokines by fexofenadine in human keratinocytes. J Dermatol Sci 2005; 38:67-69 (Pubitemid 40410634)
24. Traidl-Hoffmann C, Munster I, Ring J, et al. Impact of desloratadine and loratadine on the crosstalk between human keratinocytes and leukocytes: implications for anti-inflammatory activity of antihistamines. Int Arch Allergy Immunol 2006; 140:315-320 (Pubitemid 44114476)
25. Shimizu T, Nishihira J, Watanabe H, et al. Cetirizine, an H1-receptor antagonist, suppresses the expression of macrophage migration inhibitory factor: its potential anti-inflammatory action. Clin Exp Allergy 2004; 34:103-109 (Pubitemid 38183687)
26. Murota H, El-latif MA, Tamura T, et al. Olopatadine hydrochloride improves dermatitis score and inhibits scratch behavior in NC/Nga mice. Int Arch Allergy Immunol 2010; 153:121-132
27. Sadofsky LR, Campi B, Trevisani M, et al. Transient receptor potential vanilloid-1-mediated calcium responses are inhibited by the alkylamine antihistamines dexbrompheniramine and chlorpheniramine. Exp Lung Res 2008; 34:681-693
28. Massaad CA, Safieh-Garabedian B, Poole S, et al. Involvement of substance P, CGRP and histamine in the hyperalgesia and cytokine upregulation induced by intraplantar injection of capsaicin in rats. J Neuroimmunol 2004; 153:171-182 (Pubitemid 38950939)
29. Tamura T, Matsubara M, Amano T, et al. Olopatadine ameliorates rat experimental cutaneous inflammation by improving skin barrier function. Pharmacology 2008; 81:118-126 (Pubitemid 351182686)
30. Murota H, Bae S, Hamasaki Y, et al. Emedastine difumarate inhibits histamineinduced collagen synthesis in dermal fibroblasts. J Investig Allergol Clin Immunol 2008; 18:245-252 (Pubitemid 352031568)
31. Leonardi A, DeFranchis G, De Paoli M, et al. Histamine-induced cytokine production and ICAM-1 expression in human conjunctival fibroblasts. Curr Eye Res 2002; 25:189-196 (Pubitemid 36842948)
32. Asano K, Kanai K, Furuta A, et al. Suppressive activity of fexofenadine hydrochloride on nitric oxide production in-vitro and in-vivo. J Pharm Pharmacol 2007; 59:1389-1395 (Pubitemid 47606454)
33. De Luisi A, Mangialardi G, Ria R, et al. Antiangiogenic activity of carebastine: a plausible mechanism affecting airway remodelling. Eur Respir J 2009; 34:958-966
34. Kitaba S, Murota H, Yahata Y, et al. Novel functional aspect of antihistamines: the impact of bepotastine besilate on substance p-induced events. J Allergy (Cairo) 2009; 2009:853687
35. Vasiadi M, Kalogeromitros D, Kempuraj D, et al. Rupatadine inhibits proinflammatory mediator secretion from human mast cells triggered by different stimuli. Int Arch Allergy Immunol 2010; 151:38-45
36. Matsubara M, Masaki S, Ohmori K, et al. Differential regulation of IL-4 expression and degranulation by antiallergic olopatadine in rat basophilic leukemia (RBL-2H3) cells. Biochem Pharmacol 2004; 67:1315-1326 (Pubitemid 38315097)
37. Asano K, Furuta A, Kanai K, et al. Inhibition of angiogenic factor production from murine mast cells by an antiallergic agent (epinastine hydrochloride) in vitro. Mediators Inflamm 2008; 2008:265095
38. Wang YH, Tache Y, Harris AG, et al. Desloratadine prevents compound 48/80-induced mast cell degranulation: visualization using a vital fluorescent dye technique. Allergy 2005; 60:117-124
39. Tokura Y, Kobayashi M, Ito T, et al. Antiallergic drug olopatadine suppresses murine contact hypersensitivity and downmodulates antigen-presenting ability of epidermal Langerhans cells. Cell Immunol 2003; 224:47-54 (Pubitemid 37315580)
40. Sugita K, Kabashima K, Tokura Y. Fexofenadine downmodulates antigenpresenting ability of murine epidermal Langerhans cells. J Dermatol Sci 2008; 49:88-91 (Pubitemid 350237691)
41. Sugita K, Kobayashi M, Mori T, et al. Antihistaminic drug olopatadine downmodulates CCL17/TARC production by keratinocytes and Langerhans cells. J Dermatol 2009; 36:654-657
42. Wu P, Mitchell S, Walsh GM. A new antihistamine levocetirizine inhibits eosinophil adhesion to vascular cell adhesion molecule-1 under flow conditions. Clin Exp Allergy 2005; 35:1073-1079 (Pubitemid 41603142)
43. Mullol J, Roca-Ferrer J, Alobid I, et al. Effect of desloratadine on epithelial cell granulocyte-macrophage colony-stimulating factor secretion and eosinophil survival. Clin Exp Allergy 2006; 36:52-58
44. Watase F, Watanabe S, Kanai K, et al. Modulation of eosinophil survival by epinastine hydrochloride, an H1 receptor antagonist, in vitro. In Vivo 2008; 22:687-691
45. Hasala H, Moilanen E, Janka-Junttila M, et al. First-generation antihistamines diphenhydramine and chlorpheniramine reverse cytokine-afforded eosinophil survival by enhancing apoptosis. Allergy Asthma Proc 2007; 28:79-86
46. Vancheri C, Mastruzzo C, Tomaselli V, et al. The effect of fexofenadine on expression of intercellular adhesion molecule 1 and induction of apoptosis on peripheral eosinophils. Allergy Asthma Proc 2005; 26:292-298 (Pubitemid 41381405)
47. Ikoma A, Steinhoff M, Stander S, et al. The neurobiology of itch. Nat Rev Neurosci 2006; 7:535-547 (Pubitemid 43995431)
48. Tominaga M, Tengara S, Kamo A, et al. Psoralen-ultraviolet A therapy alters epidermal Sema3A and NGF levels and modulates epidermal innervation in atopic dermatitis. J Dermatol Sci 2009; 55:40-46
49. Heyer G, Hornstein OP, Handwerker HO. Skin reactions and itch sensation induced by epicutaneous histamine application in atopic dermatitis and controls. J Invest Dermatol 1989; 93:492-496 (Pubitemid 19225494)
50. Darsow U, Scharein E, Bromm B, et al. Skin testing of the pruritogenic activity of histamine and cytokines (interleukin-2 and tumour necrosis factor-alpha) at the dermal-epidermal junction. Br J Dermatol 1997; 137:415-417 (Pubitemid 27421571)
51. Davies MG, Greaves MW. Sensory responses of human skin to synthetic histamine analogues and histamine. Br J Clin Pharmacol 1980; 9:461-465 (Pubitemid 10077623)
52. Nishioka K, Katayama I, Doi T. Histamine release by scratching inflamed skin. J Dermatol 1987; 14:284-285
53. Wahlgren CF. Itch and atopic dermatitis: an overview. J Dermatol 1999; 26:770-779
54. Matsubara M, Tamura T, Ohmori K, et al. Histamine H1 receptor antagonist blocks histamine-induced proinflammatory cytokine production through inhibition of Ca2-dependent protein kinase C, Raf/MEK/ERK and IKK/I kappa B/NF-kappa B signal cascades. Biochem Pharmacol 2005; 69:433-449 (Pubitemid 40094503)
55. Shiohara T, Hayakawa J, Mizukawa Y. Animal models for atopic dermatitis: are they relevant to human disease? J Dermatol Sci 2004; 36:1-9 (Pubitemid 39370020)
56. Man MQ, Hatano Y, Lee SH, et al. Characterization of a hapten-induced, murine model with multiple features of atopic dermatitis: structural, immunologic, and biochemical changes following single versus multiple oxazolone challenges. J Invest Dermatol 2008; 128:79-86 (Pubitemid 350249387)
57. Tamura T, Amano T, Ohmori K, et al. The effects of olopatadine hydrochloride on the number of scratching induced by repeated application of oxazolone in mice. Eur J Pharmacol 2005; 524:149-154 (Pubitemid 41606828)
58. Murota H, Kitaba S, Tani M, et al. Effects of nonsedative antihistamines on productivity of patients with pruritic skin diseases. Allergy 2010; 65:929-930
59. Murota H, Kitaba S, Tani M, et al. Impact of sedative and nonsedative antihistamines on the impaired productivity and quality of life in patients with pruritic skin diseases. Allergol Int 2010; 59:345-354
60. Thompson AK, Finn AF, Schoenwetter WF. Effect of 60 mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria. J Am Acad Dermatol 2000; 43:24-30 (Pubitemid 30439708)
61. Church MK, Maurer M, Simons FE, et al. Risk of first-generation H(1)- antihistamines: a GA(2)LEN position paper. Allergy 2010; 65:459-466
62. Parmentier R, Ohtsu H, Djebbara-Hannas Z, et al. Anatomical, physiological, and pharmacological characteristics of histidine decarboxylase knock-out mice: evidence for the role of brain histamine in behavioral and sleep-wake control. J Neurosci 2002; 22:7695-7711 (Pubitemid 35386369)
63. Lin JS. Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons. Sleep Med Rev 2000; 4:471-503
64. Van Ruitenbeek P, Vermeeren A, Riedel WJ. Cognitive domains affected by histamine H(1)-antagonism in humans: a literature review. Brain Res Rev 2010; 64:263-282
65. Schwartz JC, Arrang JM, Garbarg M, et al. Histaminergic transmission in the mammalian brain. Physiol Rev 1991; 71:1-51
66. Lin JS, Sakai K, Jouvet M. Evidence for histaminergic arousal mechanisms in the hypothalamus of cat. Neuropharmacology 1988; 27:111-122 (Pubitemid 18052351)
67. Shamsi Z, Hindmarch I. Sedation and antihistamines: a review of inter-drug differences using proportional impairment ratios. Hum Psychopharmacol 2000; 15:S3-S30
68. Yanai K, Tashiro M. The physiological and pathophysiological roles of neuronal histamine: an insight from human positron emission tomography studies. Pharmacol Ther 2007; 113:1-15 (Pubitemid 44969926)
69. Zhang D, Tashiro M, Shibuya K, et al. Next-day residual sedative effect after nighttime administration of an over-the-counter antihistamine sleep aid, diphenhydramine, measured by positron emission tomography. J Clin Psychopharmacol 2010; 30:694-701
70. Okamura N, Yanai K, Higuchi M, et al. Functional neuroimaging of cognition impaired by a classical antihistamine, d-chlorpheniramine. Br J Pharmacol 2000; 129:115-123 (Pubitemid 30072677)
71. Masaki T, Chiba S, Yasuda T, et al. Involvement of hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity. Diabetes 2004; 53:2250-2260 (Pubitemid 39145578)
72. Fulop AK, Foldes A, Buzas E, et al. Hyperleptinemia, visceral adiposity, and decreased glucose tolerance in mice with a targeted disruption of the histidine decarboxylase gene. Endocrinology 2003; 144:4306-4314 (Pubitemid 37204829)
73. Ratliff JC, Barber JA, Palmese LB, et al. Association of prescription H1 antihistamine use with obesity: results from the National Health and Nutrition Examination Survey. Obesity (Silver Spring) 2010; 18:2398-2400
74. Murota H, Takahashi A, Nishioka M, et al. Showering reduces atopic dermatitis in elementary school students. Eur J Dermatol 2010; 20:410-411
75. Wollenberg A, Rawer HC, Schauber J. Innate Immunity in Atopic Dermatitis. Clin Rev Allergy Immunol 2010
76. Ertam I, Biyikli SE, Yazkan FA, et al. The frequency of nasal carriage in chronic urticaria patients. J Eur Acad Dermatol Venereol 2007; 21:777-780 (Pubitemid 46939050)
77. St Peter SD, Sharp SW, Ostlie DJ. Influence of histamine receptor antagonists on the outcome of perforated appendicitis: analysis from a prospective trial. Arch Surg 2010; 145:143-146
78. Metz M, Doyle E, Bindslev-Jensen C, et al. Effects of antihistamines on innate immune responses to severe bacterial infection in mice. Int Arch Allergy Immunol 2011; 155:355-360